ORLANDO, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--New research shows cardiac resynchronization therapy (CRT) may improve clinical outcomes in asymptomatic or mildly symptomatic heart failure patients, and clinical results revealed a 62 percent reduction in the risk of first heart failure hospitalization or death. The 24-month findings from the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc. (NYSE: MDT), show the potential benefits of CRT in patients with mild heart failure.
